Last reviewed · How we verify
SYHA1815
At a glance
| Generic name | SYHA1815 |
|---|---|
| Also known as | SYHA1815 tablet |
| Sponsor | Shanghai Runshi Pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYHA1815 CI brief — competitive landscape report
- SYHA1815 updates RSS · CI watch RSS
- Shanghai Runshi Pharmaceutical Technology Co., Ltd portfolio CI